Clinical trial Recruiting at 2 sites Observational Women only

Registry to evaluate the safety of SUNOSI during pregnancy

Official title: SUNOSI® (Solriamfetol) Pregnancy Registry: An Observational Study on the Safety of Solriamfetol Exposure in Pregnant Women and Their Offspring

Run by Axsome Therapeutics, Inc. · NCT06413420 · Data updated 2026-11-12

This study is trying to see if the medication SUNOSI is safe for pregnant women who have narcolepsy or sleep apnea and how it affects their babies.

More Obstructive Sleep Apnea trials

Quick facts

Study typeObservational
SexWomen only
Enrollment1731 (estimated)
SponsorAxsome Therapeutics, Inc.
Industry-sponsored
Locations2 sites (Morrisville, North Carolina and 1 other locations)
StatusRecruiting
StartedJuly 31, 2019
Main results expectedSeptember 2029
Study endsSeptember 2029
Registry record updatedOctober 5, 2026
Trial IDNCT06413420 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this registry are pregnant women of any age who have narcolepsy or obstructive sleep apnea and have been prescribed solriamfetol or other wake-promoting medications.

Probably not a fit

Patients who have experienced pregnancy outcomes prior to their first contact with the registry will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The SUNOSI Pregnancy Registry is a prospective, multi-country observational study aimed at assessing the safety of solriamfetol exposure in pregnant women diagnosed with narcolepsy or obstructive sleep apnea. This registry collects health information from enrolled participants and their healthcare providers regarding their pregnancies and the health of their babies up to one year of age. The data collected is strictly observational, relying on routine medical records to inform treatment decisions regarding solriamfetol during pregnancy.

Why it matters

Potential benefit: If successful, this registry could provide critical safety information that helps pregnant women and their healthcare providers make informed decisions about the use of solriamfetol.

How similar studies have gone: While this registry approach is observational, similar studies evaluating medication safety during pregnancy have shown success in providing valuable data for informed clinical decisions.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Pregnant women of any age
* Diagnosed with narcolepsy or obstructive sleep apnea OR has taken solriamfetol or other wake promoting medications or stimulants during pregnancy or in the relevant exposure window before conception
* Resident of the US or Canada
* Provides written informed consent to participate in the study
* Authorization for her HCP(s) to provide data to the registry

Exclusion Criteria:

* Occurrence of pregnancy outcome prior to first contact with the registry coordination center (RCC)

Where it's running

  • Evidera, a PPD business unit
    Morrisville, North Carolina, United States
    Recruiting
  • PPD, Inc.
    Wilmington, North Carolina, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.